Fisher & Paykel Healthcare Corporation LimitedASX: FPHStrong FY26 growth and FY27 guidance are overshadowed by overbought technicals.Stock Performance Profile:(Source: TradingView) 3-Month Performance Profile of FPH on a DTF compared to S&P/ASX 200 (XJO). Fisher & Paykel Healthcare delivered a strong FY2026 performance, with operating revenue rising 14% to NZ$2.31 billion.
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
